Nicox completes transfer of Commercial Operations to new pan-European Ophthalmic Specialty Pharmaceutical Company led by GHO Capital


SOPHIA ANTIPOLIS, France, Aug. 10, 2016 (GLOBE NEWSWIRE) — Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of the transfer of its European and International commercial operations and related late-stage development programs to a newly-founded, private, pan-European ophthalmic specialty pharmaceutical company. This transfer includes the affiliates Nicox Pharma (France), together with its Spanish and UK operations, Nicox GmbH (Germany), Laboratoires Nicox (France) and Nicox Farma (Italy), all commercial products and the rights (and associated agreements) to AzaSite®, AzaSite Xtra®, BromSiteTM for Europe, Middle East and Africa and NCX 4240 outside of Japan and North America. No other Nicox affiliates, operations or programs are included in or affected by this transaction. 

Nicox will receive a €9 million cash payment from GHO Capital as a result of the completion of this transaction. For further information on the transaction, please refer to Nicox’s Press Release dated July 5, 2016.


About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international R&D company focused on the ophthalmic market. For more information on Nicox, its products or pipeline, please visit:

Analyst coverage

Bryan, Garnier & Co       Hugo Solvet                    Paris, France
Invest Securities             Martial Descoutures       Paris, France
Gilbert Dupont                Damien Choplain           Paris, France
Stifel                                 Max Hermann                   London, UK


Upcoming financial and business conferences

September 11-13             Rodman & Renshaw Annual Global Investment Conference                               New York, US
October 5-6                     Large & Midcap Event                                                                               Paris, France
November 15-16             Stifel 2016 Healthcare Conference                                                          New York, US
November 18-19             Actionnaria                                                                                                Paris, France
November 21-23             Deutsches Eigenkapitalforum                                                                  Frankfurt, Germany
December 13                   Guggenheim Securities 4th Annual Boston Healthcare Conference   Boston, US

Nicox                              Gavin Spencer | Executive Vice President Corporate Development
                                        Tel +33 (0)4 97 24 53 00 |    

Media Relations           

United Kingdom               Jonathan Birt
                                        Tel +44 7860 361 746 |

France                            NewCap | Nicolas Merigeau
                                        Tel +33 (0)1 44 71 94 98 | 

United States                  Argot Partners | Eliza Schleifstein
                                        Tel +1 (917) 763-8106 |

Investor Relations       

Europe                            NewCap | Julien Perez | Valentine Brouchot
                                        Tel +33 (0)1 44 71 94 94 |

United States                  Argot Partners | Melissa Forst
                                        Tel +1 (212) 600-1902 |

The information contained in this document may be modified without former notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Press release




Leave A Reply